Abstract
Hyperthermic intraperitoneal chemotherapy (HIPEC) is promoted by some as a standard treatment for peritoneal carcinomatosis of epithelial ovarian cancer (EOC) and other tumor entities, despite lack of robust data supporting this. Publicly available evidence addressing the value of HIPEC in EOC is rather inconclusive, revealing contradictory and inconsistent results while some studies even report harm to the patients from a higher morbidity. On this ground, we cannot recommend the implementation and use of HIPEC outside of a randomized clinical trial setting.
This is a preview of subscription content, log in via an institution to check access.
References
Verwaal VJ, van Ruth S, de Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21(20):3737–3743
Harter P, Mahner S, Hilpert F et al (2013) Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe Frauenheilkd 73(3):221–223
Harter P, du Bois A, Mahner S et al (2016) Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. Geburtshilfe Frauenheilkd 76(2):147–149
Quenet F, Elias D, Roca L. A Unicancer phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 36;2018 (suppl; abstr LBA3503)
Spiliotis J, Halkia E, Lianos E et al (2015) Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22(5):1570–1575
Harter P, Reuss A, Sehouli J, Chiva L, du Bois A. Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al
Van Driel W, Sikorska K, Schagen van Leeuwen J, et al. A phase 3 trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer. J Clin Oncol. 35;2017 (suppl; abstr 5519)
Lim MC, Chang S-J, Yoo HJ, et al. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 35;2017 (suppl; abstr 5520)
van Driel WJ, Koole SN, Sikorska K et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 378:230–240
Spriggs DR, Zivanovic O (2018) Ovarian cancer treatment—are we getting warmer? N Engl J Med. 378(3):293–294
Vergote I, Chiva L, du Bois A (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 378(14):1362–1363
Fotopoulou C, Sehouli J, Mahner S et al (2018) HIPEC: HOPE or HYPE in the fight against advanced ovarian cancer? Ann Oncol. https://doi.org/10.1093/annonc/mdy198
Funding
Not applicable.
Author information
Authors and Affiliations
Contributions
Protocol/project development: Harter, Fotopoulou. Data collection or management: all authors. Data analysis: all authors. Manuscript writing/editing: all authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Harter, P., du Bois, A., Sehouli, J. et al. Is there a role for HIPEC in ovarian cancer?. Arch Gynecol Obstet 298, 859–860 (2018). https://doi.org/10.1007/s00404-018-4908-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-018-4908-0